Cap-Dependent Translation Inhibitors for p53 Reactivation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer therapies face challenges in effectively targeting and reactivating the p53 tumor suppressor protein in cancer cells that retain wild-type p53, often relying on DNA-damaging agents that can cause collateral damage to normal cells.

Innovation Solution

The development of small molecule cap-dependent inhibitors, such as 4Ei-10, which inhibit cap-dependent protein translation, leading to increased IRES activity and accumulation of the p53 tumor suppressor protein without inducing DNA damage, thereby inducing cell cycle arrest and apoptosis in cancer cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If DNA-damaging agents are used to target cancer cells, then cancer cell death is achieved, but collateral damage to normal cells occurs

Engineering Contradiction:

Improvecancer cell targeting effectivenessVSAvoidcollateral damage to normal cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention changes the mechanism parameter from DNA damage to cap-dependent translation inhibition. By targeting the eIF4E-eIF4G interaction, the therapy alters the fundamental parameter of cancer cell vulnerability from genomic integrity to protein synthesis dependency, achieving selective cancer cell death without DNA damage to normal cells

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention exploits the local quality difference between cancer and normal cells regarding eIF4E overexpression. Cancer cells have elevated eIF4E levels and heightened dependency on cap-dependent translation, creating a localized therapeutic vulnerability that normal cells lack, enabling selective targeting

Inventive Principle:

Principle #3Local quality

2Reliability

If cap-dependent protein translation is inhibited to induce p53 accumulation, then apoptosis in cancer cells is achieved, but the mechanism complexity increases

Engineering Contradiction:

Improveapoptosis induction effectivenessVSAvoidmechanism complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The invention uses eIF4E inhibition as an intermediary to indirectly activate p53. Rather than directly targeting p53 or its regulatory pathways, the compound 4Ei-10 mediates its effect by blocking cap-dependent translation, which triggers IRES-mediated p53 synthesis as a downstream consequence, simplifying the direct interaction while maintaining pathway complexity

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention inverts the conventional approach to p53 activation. Instead of directly stimulating p53 or inhibiting its degradation, it blocks cap-dependent translation to force a switch to IRES-mediated translation, thereby indirectly increasing p53 levels through an alternative synthetic pathway

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS11439656B2Pharmaceutical compounds and uses thereof

Publication Date: 2022.09.13 REGENTS OF THE UNIVERSITY OF MINNESOTA

AI summary

Described herein are small molecule cap-dependent inhibitors, including the compound of the formula:which compounds that can induce the accumulation of the p53 tumor suppressor protein in cancer cells that still express wild-type p53, as well as methods of using those compounds to, among other things, treat neuroblastoma, pediatric glioblastoma multiforme or breast cancer.